561 results about "Immune protection" patented technology

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention belongs to the technical field of biological medicines, and discloses a recombinant protein and application thereof in preparation of fish vaccines. According to the invention, CP4 protein of nervous necrosis virus of grouper is taken as antigen for vaccine, recombinant Escherichia coli BL21 (pET32a-CP4) capable of expressing the protein is constructed by means of genetic engineering technology, recombinant protein rCP4 is obtained through induced expression, and oxidized single-walled carbon nanotubes are taken as carriers to prepare the grouper immersion vaccine (namely SWCNT-rCP4 vaccine). According to the SWCNT-rCP4 vaccine provided by the invention, the immunization of the grouper can be realized through soaking immunization, the survival rate of the grouper reaches 85% after the grouper is soaked and immunized for 4w and then is infected with NNV, and the immune protection effect is remarkable.

The invention belongs to the technical field of gene engineering, and particularly discloses a construction method and application of a toxoplasma gondii gene knockout vaccine strain, a TGGT1202920 gene of toxoplasma gondii is directly knocked out through a gene editing technology to obtain a delta TGGT1202920 strain, and the strain has the characteristics that the strain can be normally cultured in vitro and is almost non-toxic in vivo; after animals are immunized with delta TGGT1202920 strains, good immune protection can be generated, infection of wild type toxoplasma gondii can be resisted, and the strain can be used for preparing toxoplasmosis resistant vaccines to prevent toxoplasma gondii infection.

The present invention discloses a vaccine adjuvant, a vaccine composition, and a preparation method and application thereof, relating to the field of veterinary technology. The present invention uses safe, stable, and efficient lipophilic and hydrophilic surfactants, which can reduce the body's side effects and accumulation in the body, and has the technical advantage of high safety. The invention helps to improve the quality of veterinary vaccines and reduce the production costs of veterinary vaccine manufacturers. After the vaccine adjuvant is prepared into a vaccine composition, it can effectively enhance the immunogenicity of the vaccine, improve the vaccine's immune effect, and provide long-term and stable immune protection.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention discloses mRNA, an mRNA-LNP vaccine of the mRNA, a preparation method and application of the mRNA-LNP vaccine. The invention discloses an H5 subtype avian influenza virus vaccine, and aims to provide a vaccine which combines a mosaic sequence with an mRNA vaccine, achieves a good effect in an immune protection experiment of chickens, and can realize cross protection of branched strains of H5 subtype avian influenza virus 2.3. 4.4b and 2.3. 4.4 hours. According to the technical scheme, the nucleotide sequence of the mRNA is as shown in SEQ ID NO. 1; the nucleotide sequence of the mRNA is a Mosaic sequence which is obtained by designing a gene sequence of a 2.3. 4.4b branch strain of the avian influenza H5N6; the mRNA-LNP vaccine comprises mRNA (Messenger Ribonucleic Acid) with a nucleotide sequence as shown in SEQ ID NO. 1; belongs to the technical field of biology.

The invention discloses a streptococcus suis type 2 gene deletion strain as well as a construction method and application thereof, and belongs to the technical field of biological products. According to the invention, the B9H0105210 gene in the genome of the streptococcus suis serotype 2 SC19 is deleted in a homologous recombination manner for the first time, the hydrogen peroxide and nitric oxide stress resistance of the constructed streptococcus suis serotype 2 gene deleted strain is reduced, and the pathogenicity to mice is obviously weakened; moreover, the growth performance of the streptococcus suis type 2 gene-deleted strain is not greatly different from that of a wild strain SC19, the condition of gene recovery does not exist after continuous passage, and the streptococcus suis type 2 gene-deleted strain has an application prospect as an attenuated live vaccine, has a good immune protection effect on different genotypes of streptococcus suis such as the streptococcus suis type 2 strain SC19 and streptococcus suis type 2 P1 / 7, and has a good application prospect. And a certain cross immune protection performance is achieved.

The invention relates to the technical field of bioengineering, and particularly discloses a chicken infectious anemia virus, a chicken infectious anemia virus egg yolk antibody and a preparation method and application thereof. The invention relates to a chicken infectious anemia virus, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and is named as the chicken infectious anemia virus RD240101A, the preservation date is September 23, 2024, and the preservation number is CGMCC NO.46198. The chicken infectious anemia virus has the advantages that the chicken infectious anemia virus is named as the chicken infectious anemia virus RD240101A; the chicken infectious anemia virus egg yolk antibody is prepared by taking an inactivated vaccine prepared from the chicken infectious anemia virus RD240101A as an immunogen, is high in specificity and good in safety, does not have any local or whole-body adverse reaction caused by injection of the antibody after being inoculated to chicks, can provide effective immune protection for chicken flocks, and can be used for preparing the chicken infectious anemia virus egg yolk antibody. And the method has a good commercial development prospect.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention provides a larimichthys crocea iridovirus inactivated vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of viral vaccines. The larimichthys crocea iridovirus inactivated vaccine comprises an inactivated larimichthys crocea iridovirus and an adjuvant, and the strain of the larimichthys crocea iridovirus is an FD201807 strain. After the larimichthys crocea iridovirus inactivated vaccine is injected, the phenomena of ingestion and abnormal behaviors of fishes are avoided, the death phenomenon is avoided, the safety is high, the relative immune protection rate of the inactivated vaccine to immunized fishes is 51.20% or above, the immune effect is good, and the larimichthys crocea iridovirus inactivated vaccine can be applied to prevention and treatment of larimichthys crocea iridovirus diseases. The preparation method of the larimichthys crocea iridovirus inactivated vaccine is simple and convenient, easy to operate, low in cost and suitable for industrial production.

The invention belongs to the technical field of biological medicine, and discloses an application of recombinant protein in preparation of a snakehead vesicular virus vaccine. A G protein of a snakehead vesicular virus (SHVV) is taken as an antigen for the vaccine, recombinant escherichia coli BL21 (pET32a-G) capable of expressing the protein is constructed by utilizing a genetic engineering technical means, recombinant protein rG is obtained through induced expression, and the nano-carrier vaccine (BNC-rG vaccine) of the snakehead vesicular virus is prepared by taking bacterial nano-cellulose as a carrier. According to the BNC-rG vaccine provided by the invention, immune protection against SHVV can be realized through immersion immunization, the specific antibody level is remarkably improved, the relative protection rate of snakehead reaches 80.00% after snakehead is infected with SHVV after immersion immunization for 4 weeks, and the immune protection effect is remarkable.

The present invention relates to CpG oligodeoxyribonucleotides with improved body immunity, combinations thereof with additional adjuvants, and uses of the CpG adjuvants or combinations thereof in various vaccine compositions. The CpG independently serves as an adjuvant or is combined with an existing marketed adjuvant for use, and the CpG has the very remarkable advantages that the immune effect is advanced, the immune effect is improved, the lasting period of the immune protection effect is longer, the potential anaphylactic reaction is lower and the like, is superior to a commercially available vaccine adjuvant or an adjuvant system, and is a very excellent effective component of the vaccine adjuvant or the vaccine adjuvant system.

The invention relates to the field of veterinary vaccines, in particular to a porcine pseudorabies virus antigen, a porcine pseudorabies subunit vaccine as well as a preparation method and application of the porcine pseudorabies virus antigen and the porcine pseudorabies subunit vaccine. The porcine pseudorabies virus antigen is porcine pseudorabies virus gD protein, and the amino acid sequence of the porcine pseudorabies virus gD protein is as shown in SEQ ID NO: 1. The porcine pseudorabies subunit vaccine prepared from the porcine pseudorabies virus antigen is simple in preparation method, high in neutralizing antibody value, strong in antigen immunity, capable of effectively activating immune response of a body and capable of playing a good immune protection role on porcine pseudorabies.

The invention discloses a monkey pox virus epitope mRNA composition and application thereof, and relates to the technical field of biological medicines. The monkey pox virus epitope mRNA composition comprises mRNA encoding an epitope or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the epitope and having the same immunogenicity. The vaccine can generate a high-level immune protection effect aiming at the monkey pox virus, can be used for preparing a medicine for preventing and treating the monkey pox virus, and has a wide application prospect clinically.

The invention provides a gntR17 gene deleted strain M5 delta gntR17 as well as a construction method and application thereof, and belongs to the technical field of biology. The M5 delta gntR17 strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is July 4, 2024, and the preservation number is CGMCC NO.46061. The M5 delta gntR17 strain is preserved in the China General Microbiological Culture Collection Center (CGMCC). It is found that the gntR17 gene is a related gene affecting the virulence of the brucella, the virulence of the brucella can be weakened by deletion of the gntR17 gene, the safety is improved, the survival ability of the brucella in cells and a mouse body can be remarkably reduced after deletion of the gntR17 gene, and the gntR17 gene has potential application value. Compared with the original brucella M5 strain, the M5 delta gntR17 strain constructed after the gntR17 gene is knocked out has the advantages that the virulence is weakened, the safety is high, the immune protection similar to that of an M5-90 delta 26 vaccine is realized, and the strain can be used as a candidate attenuated live vaccine strain for preventing animal brucellosis.

The invention discloses an African swine fever virus T cell epitope peptide for inducing swine T cell immune response and a composition of the African swine fever virus T cell epitope peptide. The amino acid sequence of the African swine fever virus T cell epitope peptide is shown as any one of SEQ ID NO.1-19. Or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1-19 and maintains the protein function shown in SEQ ID NO.1-19 through substitution and / or deletion and / or addition of one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1-19; the composition comprises amino acids of which the sequences are SEQ ID NO.1-19. A group of ASFV key T cell antigens and epitope peptides are obtained by combining IFN-gamma ELISpot and flow cytometry screening, the ASFV key T cell antigens and epitope peptides can be used as vaccine components to induce strong T cell immune response, and T cells activated by the antigen peptides have the maximum immune protection potential and are essential key antigens for ASFV vaccine research and development.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention relates to a gene, a protein and a plasmid of a trachinotus ovatus apoptosis regulatory factor Bok and application of the gene, the protein and the plasmid, and belongs to the field of molecular biology, the sequence of cDNA nucleotide of the trachinotus ovatus apoptosis regulatory factor Bok is as shown in SEQ ID NO.1, and the amino acid sequence is as shown in SEQ ID NO.2. The invention further provides a construction method of the eukaryotic expression plasmid of the trachinotus ovatus apoptosis regulatory factor Bok. The regulation effect of the constructed eukaryotic expression vector on other apoptosis-related factors of the trachinotus ovatus is verified, and after the eukaryotic expression plasmid for the apoptosis regulation factor Bok of the trachinotus ovatus is injected into a fish body, the disease resistance of the fish body can be remarkably improved, and a remarkable immune protection effect is achieved.

The invention discloses a recombinant Getai virus for expressing H1N1 subtype swine influenza virus HA protein, the virus has an H1N1 subtype swine influenza virus HA1 protein gene, and the HA1 protein gene is located between E1 and 3 'UTR genes of a Getai virus genome. Accordingly, a corresponding construction method is also established. Furthermore, a corresponding recombinant Geitai virus inactivated vaccine is also developed. Researches show that the inactivated vaccine is used for immunizing mice, can well induce test animals to generate specific antibodies aiming at the H1N1 subtype swine influenza virus, also can generate specific antibodies for expressing the Geitai virus, and provides immune protection for attack of the H1N1 subtype swine influenza virus; and the H1N1 subtype swine influenza virus and Getah virus bivalent inactivated vaccine is successfully prepared. Therefore, the invention has a better effect on prevention and control of the H1N1 subtype swine influenza virus, lays a foundation for the Geitai virus as a carrier to express other exogenous genes, is expected to be used clinically, and can protect a pig farm from being attacked by the two viruses at the same time.

Disclosed herein are methods of producing low immunogen cells and methods of using low immunogen cells to treat mammalian diseases and to prepare biomimetic nanovesicles (BioNVs). The method comprises (a) reducing or eliminating the expression and / or activity of one or more immunogenic proteins in a cell; and (b) expressing or increasing the expression and / or activity of one or more immunoprotective proteins in the cell, thereby producing the low immunogen cell.

The invention provides an efficacy-prolonged new coronavirus self-replicating nucleic acid vaccine, a product capable of being prepared from the vaccine and application of the vaccine. According to the saRNA vaccine provided by the invention, the innate immunomodulator is introduced to improve the immunogenicity of saRNA, so that enough immune response is induced under single-needle inoculation with lower dose, and immune protection on various new coronaviruses and mutants thereof is provided.

The invention belongs to the technical field of biology, and discloses a construction method of a swine cholera attenuated salmonella recombinant strain capable of simultaneously expressing a haemophilus parasuis outer membrane protein GAPDH gene and an Omp26 gene, a plasmid connected with the haemophilus parasuis GAPDH gene and the Omp26 gene is adopted to transfect a swine cholera salmonella asd gene deleted strain, screening is carried out, and screening is carried out to obtain the swine cholera attenuated salmonella recombinant strain capable of simultaneously expressing the haemophilus parasuis outer membrane protein GAPDH gene and the Omp26 gene. The recombinant attenuated salmonella choleraesuis expressing the haemophilus parasuis GAPDH gene and the Omp26 gene is obtained. The strain can simultaneously express a haemophilus parasuis outer membrane protein GAPDH gene and an Omp26 gene, and compared with a strain which singly expresses Omp26, the strain has the advantage that the immune protection effect is obviously improved. Meanwhile, the invention also provides a construction method and application of the strain.

The invention provides crab feed capable of improving the quality of crab cream. The feed is prepared from the following raw materials in parts by weight: 15-25 parts of white fish meal, 10-15 parts of fermented soybean meal, 50-60 parts of squid visceral meal, 45-50 parts of krill meal, 25-30 parts of beer yeast, 200-220 parts of high gluten flour, 45-50 parts of wheat bran, 10-20 parts of soybean lecithin oil, 5-10 parts of a vitamin premix special for crabs and 5-10 parts of a mineral premix special for crabs. According to the crab feed capable of improving the quality of the crab cream, on the basis of ensuring the ingestion and intestinal health of crabs, conditions are created for efficient nutrient absorption and utilization, then gonad development and flavor substance accumulation are driven through key substances, meanwhile, a three-dimensional anti-oxidation and immune protection system runs through all the time, the body health is guaranteed, and the crab feed has the effects of improving the crab cream quality and improving the crab cream quality. The method has the advantages of simple operation, stable color and flavor of the crab cream, sufficient energy supply in the whole process, and synergistic operation of all the systems, so that the disease resistance and survival rate of crabs are improved, and the accumulated nutrient substances are efficiently converted into the plump degree, delicious flavor and attractive color of the crab cream.